AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$25.70
arrow_upward
+1.30%(+0.33) 1D
Oct 6, 11:50:53 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMPH...
Open
$25.54
High
$25.76
Low
$25.03
Mkt. cap
1.10B
Avg. vol.
486.53K
Volume
107.06K
P/E ratio
15.03
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.90
Shares outstanding
42.54M
No. of employees
2K
Open
$25.54
High
$25.76
Low
$25.03
Mkt. cap
1.10B
Avg. vol.
486.53K
Volume
107.06K
P/E ratio
15.03
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.90
Shares outstanding
42.54M
No. of employees
2K
News stories
From web sources and news partners
Zacks
·
2 hours ago
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorPharmaceutical industry
Websiteamphastar.com